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ABSTRACT
Objectives: This retrospective cohort study aimed to compare the cost-effectiveness of using D10-CaGluconate and D5 1/4NS preparations in normal-
weight neonatal patients with Respiratory Distress Syndrome (RDS) in Kambang General Hospital, Jambi, Indonesia.
Methods: The research was conducted from September 2014 to June 2015. The study participants were divided into two groups; D10-CaGluconate 
was administered to 40 patients and D5 1/4NS to 43 patients. Effectiveness was assessed based on the changes in the physical examination results, 
average weight gain (28.48 and 23.49 g/day), blood glucose levels (26.73 and 26.42 mg/dL), respiratory rate (−12.35 breaths/minute and −7.77 
breaths/minute), pulse frequency (−10.98 and −8.07 ±), and body temperature (0.013°C and 0.012°C) of the patients in the D10-CaGluconate and 
D5 1/4NS groups, respectively.
Results: The average direct medical costs of using D10-CaGluconate and D5 1/4NS were 458,290 IDR and 408,347 IDR, respectively. The average cost-
effectiveness ratio value of total direct medical costs for D10-CaGluconate preparation was 35,207,467 IDR while that for D5 1/4NS was 33,958,602 
IDR. The direct medical cost of the incremental cost-effectiveness ratio mean value of the D5 1/4NS preparation that compared to the D10-CaGluconate 
preparation was 10,017,210 IDR.
Conclusions: The parenteral nutrition preparation of D10-CaGluconate is more cost-effective than that of D5 1/4NS.
Keywords: D10-CaGluconate, D5 1/4NS, Effectiveness, Direct medical costs, Incremental cost-effectiveness ratio.
INTRODUCTION
Health is one of the basic human rights. The 1945 Constitution of the 
Republic of Indonesia assures optimal access to health services for every 
Indonesian, including those with financial disadvantages. Indonesia is 
committed to achieving the Millennium Development Goals (MDGs) 
target from 2000 to 2015. One of the strategically planned programs 
designed by the Ministry of Health for the period 2010-2014 to achieve 
the MDGs is the National Health Insurance Program [1]. The health 
systems have established three goals: Creating fairness in health-care 
financial management, improving health status, and enhancing the 
responsiveness of medical services [2]. Under the goal of health-care 
financial management, it must be assured that the entire health fund 
is optimally distributed to ensure adequate and optimal health-care 
services for all citizens. This means that the government must develop 
an efficient health financing system to fulfill all the health needs of each 
citizen [2]. Increasing the cost-effectiveness of drugs would improve 
the efficiency of the national health financing system at the Government 
level as well as at local levels, such as in hospitals. Pharmacoeconomics 
is the study of the economic aspect of drugs, including the cost-
effectiveness [1]. The results of such pharmacoeconomic studies can be 
used for determining and developing the most efficient method of using 
limited health resources.
The Kambang General Hospital is a private hospital located in Jambi 
City, Jambi Provinces, Indonesia. It is a referral hospital, which accepts 
and treats neonatal emergency patients referred by other hospitals. 
This hospital has continuous positive airway pressure facility, which 
is used for treating neonates in emergencies, especially in the case of 
respiratory system disorder (RDS). The number of neonatal patients 
with a diagnosis of RDS is the highest case in the Kambang Hospital. 
Since 2013, the Kambang Hospital has used parenteral nutrition 
preparations to treat RDS patient. Two types of preparations are 
used: D10-CaGluconate and D5 1/4NS. These two products are the 
treatments of choice for normal-weight neonatal patients with RDS. 
D10-CaGluconate (1000 mL) consists of 100 g Dextrosa and 6-8 mL/kg/
weight CaGluconate. On the other hand, 1000 mL of D5 1/4NS consists 
Na (38.5 mEq), Cl (38.5 mEq), with composition of dextrose 50 g and 
NaCl 2.25 g (MIMS, 2013). D10-Gluconas increases the blood glucose 
level rapidly; however, it involves a higher risk of hyperglycemia. It can 
also lead to hyperxemia; therefore, calcium gluconas is administered 
simultaneously. In contrast, D5 1/4NS increases blood glucose gradually, 
causing the low risk of hyperglycemia. To the best of our knowledge, no 
research has been done to assess the cost-effectiveness of these two 
preparations. In addition, the cost-effectiveness analysis at Kambang 
Hospital is important due to a large quantity of these preparations. 
Therefore, we planned this study with the aim of determining the cost 
effectiveness of these parenteral nutrition preparations in neonatal 
patients, the treatment duration, and the direct medical cost involved. 
We believe that this study will be useful in developing the protocol, 
establishing the standard treatment cost, and assessing the cost-
effectiveness of treatment in Kambang Hospital. This will enable the 
provision of cost-effective parenteral nutrition for neonatal health 
services in the JKN era.
METHODS
This retrospective cohort study was conducted in the Kambang Hospital 
in Jambi city in 2015. We used secondary data from the medical records 
of normal-weight neonatal patients who were administered the 
parenteral nutrition preparations D10-CaGluconate and D5 1/4NS in 
Kambang Hospital. The total sampling technique was used. 371 patients 
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were treated in 2013 and 448 in 2014; this added up to 819 patients 
who were treated at the hospital from January 2013 to December 
2014. Normal-weight neonatal patients who were hospitalized at the 
Kambang Hospital for RDS and were administered parenteral nutrition 
preparations D10-CaGluconate and D5 1/4NS were included in the 
study. Neonatal patients, who did not recover, deteriorated, died during 
treatment, were discharged against medical advice from the Kambang 
Hospital, experienced hyperglycemia, were low birth weight neonates, 
or had incomplete medical records were excluded.
The parenteral nutrition preparations D10-CaGluconate and D5 1/4NS 
were the independent variables. Cost and clinical effectiveness 
parameters of weight gain, blood glucose level, respiratory rate, pulse 
frequency, and body temperature were the dependent variables. The 
confounding variables were age, gestational age, sex, comorbidities, 
socioeconomic status, and insurances. Patients’ data regarding age, 
condition at birth, medical history regarding illnesses, and other 
observations who used parental nutrition were collected from the 
medical records of the Kambang Hospital. The data were analyzed using 
univariate analysis to obtain the frequency distribution and proportions 
of all the variables such as the medical cost, clinical effectiveness, age, 
sex, comorbidities, socioeconomic status, and insurances. Chi-square 
bivariate analysis was used to study the relationship between the 
variables and the effects of each independent and confounding variable 
on the dependent variables.
RESULTS
As shown in the Table 1, the majority of patients treated in the 
perinatology room at the Kambang Hospital, Jambi comprised 
neonates aged 1-14 days; 97.5% were under treatment with 
preparation A (D10-CaGluconate), and 86% with preparation B 
(D5 1/4NS) with 83.5% patients were treated with both preparation 
A and B. There were no marked sex differences in the treatment 
groups. Group A had an equal proportion of boy and girl patients 
(50%); however, in Group B, the proportion of boys was greater 
(55.8%) than that of girls (44.2%). Majority of the neonates (55%) 
in Group A had a gestation age ≥36 weeks. In addition, most patients 
in Group A were born at full gestational age and had a normal birth 
weight, followed by those born at a gestational age of 32-35 months 
(37.5%), and 28-31 months (7.5%). In Group B, most patients were 
born at ≥36 weeks of gestation (83.7%), followed by those born at 
32-35 weeks (16.3%). We found that most patients in Group B were 
also born at full gestational age. None of the patients in Group B was 
born at 28-31 weeks of gestation.
More patients in Group A had a comorbidity (accompanying disease) 
(72.5%) than those in Group B (67.4%). All study participants had a 
normal birth weight (>2500 g); 45% of Group A and 16.3% of Group B 
patients were born prematurely but had normal birth weight. One of the 
factors contributing to this is the food consumed by the mother during 
pregnancy. The demographic data revealed that in Group A, 67.5% of 
the parents were private employees, 20% were entrepreneurs, and 
12.5% were government employees. By contrast, in Group B, 67.4% 
parents were private employees, 18.6% were entrepreneurs, and 14% 
were government employees. The Kambang Hospital is affiliated to 
several insurance companies; therefore, many of the patients’ parents 
used company insurance to pay for the treatment.
This study included neonates diagnosed with RDS. According to 
the Indonesian Doctor Association (Ikatan Dokter Indonesia) 
(2011) [3], RDS, also known as hyaline membrane disease (HMD), is a 
respiratory disorder caused by pulmonary immaturity and surfactant 
deficiency [4]. It usually develops in premature neonates born before 
34 weeks of gestation and low birth weight neonates weighing <1500 g. 
Surfactants is formed at a gestational age of 24-28 weeks; therefore, 
the incidence of HMD is inversely proportional to the gestational age. 
The incidence rate of HMD is 60% in neonates born before 30 weeks 
of gestation, 25% in those born at 30-34 weeks, and 5% in those born 
at 35-36 weeks. Other predisposing factors are maternal diabetes and 
cesarean delivery [4].
According to the patients’ clinical weight data, the mean birth weight 
of the patients in Group A was 2.940±368.504 mg and that of those 
in Group B was 3,131.40±348.128 mg. Premature neonates formed 
the second largest majority in Group A. The average weight gain in 
neonates was 20-30 g/day after receiving parenteral nutrition for 
1 day. This result was similar to that reported by the Indonesia Pediatric 
Society (Ikatan Dokter Anak Indonesia) [5]. When the neonates’ 
condition improves, parenteral nutrition can be replaced by enteral 
nutrition (breast milk or formula milk). Prolonged consumption of high 
concentrations of parenteral nutrition can cause phlebitis.
Clinical parameters, including weight, blood glucose level, respiratory 
rate, pulse frequency, and body temperature of the neonates in 
both groups were assessed to compare the effectiveness of both the 
Table 1: Basic characteristic of participants according to the treatment groups
Parameters total (%) Preparation A n=40 (%) Preparation B n=43 (%) p
Patient’s age (days)
1-14 39 (97.5) 38 (88.4) 0.109a
15-30 1 (2.5) 5 (11.6)
Pregnancy age (gestation) (weeks)
28-31 3 (7.5) 0 (0) 0.010b
32-35 15 (37.5) 7 (16.3)
≥36 22 (55) 36 (83.7)
Sex
Male 20 (50) 24 (55.8) 0.596a
Female 20 (50) 19 (44.2)
Comorbid
Hyperbilirubinemia/icterus/jaundice 2 (5) 5 (11.6) 0.534b
Neonatal infection/sepsis 9 (22.5) 8 (18.6)
Others 29 (72.5) 29 (69.8)
Social economic
Government employees 5 (12.5) 6 (14) 0.973b
Non-government employees (private employees) 27 (67.5) 29 (67.4)
Entrepreneur (farmer, other) 8 (20) 8 (18.6)
Insurance
BPJS 18 (45) 17 (39.5) 0.418b
Company 1 (2.5) 4 (9.3)
General 21 (52.5) 22 (51.2)
aAnalysis by Chi-square, banalysis by Fisher’s exact test
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parenteral nutrition preparations. All of these are vital parameters that 
must be examined during a physical examination.
Table 2 shows that the effectiveness score of the increase in body 
weight was by 20-30 g/day and the blood glucose level ranged from 
0 to 30 mg/dL in the neonates. Respiratory rate, pulse frequency, and 
body temperature were divided into two categories: Returning to 
normal and not returning to normal. The value for normal respiratory 
rate was 30-60 breaths/minute, that for normal pulse frequency was 
100-160 breaths/minute, and that for normal body temperature was 
36.5-37.5°C. The data were assessed using the Chi-square test.
Participants and the clinical effectiveness ratio were determined 
using the values of average weight gain and blood glucose levels of the 
neonates. The effectivity scores of respiratory rate, pulse frequency, and 
body temperature were divided into “returning to normal” and “not 
returning to normal” categories.
The mean increase in the weight of the neonates in Group A was 
28.48±3.464 g/d and that in those belonging to Group B was 
23.49±4.3 g/day. The mean blood glucose level in patients of 
Group A was 26.72±7.841 mg/dL and that of those in Group B was 
26.42±10.147 mg/dL. The respiratory rate and pulse frequency 
returned to normal in 85% patients of Group A and in 76.7% and 
79.1% patients in Group B, respectively. Finally, the body temperature 
of 62.5% and 69.8% patients in Groups A and B, respectively, returned 
to normal.
Based on the data regarding clinical parameters of both the groups, 
the effectivity percentage for Group A was larger than that for Group B, 
although Group B had a higher sample size than Group A (n=43 [52%] 
vs. n=40 neonates [48%]). RDS patients experience hypoglycemia; 
therefore, when the condition is left untreated, it could cause brain 
destruction and death. The mean weight of the neonates was ≥2500 g, 
and 50% of them were born at full gestational age. This could be 
attributable to immature or improper functioning of their body organs, 
increasing the risk of hypoglycemia and other infections.
The data were assessed for normality; however, the data did not follow 
a normal distribution, except for the effectivity score of the increase in 
blood glucose level which appears to follow a normal distribution. The 
effectivity score of the increase in the blood glucose level was studied 
using parametric t-test methods. The Mann–Whitney U-test was used 
to study the effectivity score of the increase in the neonates’ weight, 
respiratory rate, pulse frequency, and body temperature as these data 
were not normally distributed. Based on the results of the Mann–Whitney 
test, there was a significant difference between the effectivity score of the 
increase in neonates’ weight (20-30 g/day) (with p<0.05). Fisher’s test 
also showed a statistically significant correlation between gestational age 
and type of parenteral nutrition preparation with pregnancy age score 
(p=0.010).
The direct medical cost data were also assessed for normal 
distribution; these data were normally distributed. Parametric 
tests were then used to study variables such as the pre- and post-
treatment weight; the pre- and post-treatment pulse frequency; and 
direct medical cost components, including the costs for laboratory 
examination, doctor visit, room, and total direct medical cost. 
Parametric t-test showed that although there were differences in 
the average costs of some components, there were no significant 
differences in the laboratory examination cost (p=0.474), doctor visit 
cost (p=0.648), room cost (p=0.629), and total direct medical cost 
(p=0.980) of the two groups.
The Mann–Whitney statistical test was employed to compare the 
difference in the costs of both the parenteral nutrition preparations. 
There were statistically significant differences between the costs of 
the two treatments (p=0.000). It can be concluded that there were 
significant differences in the gestational age, effectivity score of weight 
gain in infants, and parenteral nutrition costs between the two groups 
of parenteral nutrition preparations.
Based on direct medical cost data, the mean direct medical cost in 
Group A was higher (458.290±23.828 IDR) than that in Group B 
(408.347±19.728 IDR). This could be attributable to the parenteral 
nutrition preparations, which have a higher distribution and provision 
cost than conventional nutrition. Total direct medical cost for both 
preparations includes the cost of making the parenteral nutrition 
preparations, laboratory examination cost, disposable material cost, 
doctor visit cost, and room cost for the period 2013-2014. Parenteral 
Table 2: Parameters of cost‑effectiveness in each treatment group
Parameter Effectiveness (total [%]) p
Preparation A (n=40) Preparation B (n=43)
Weight (g)
Increasing weight gain 28.48±3.464 23.49±4.3 0.000b
Blood glucose level (mg/dL)
Increasing blood glucose level 26.72±7.841 26.42±10.147 0.879a
Respiratory rate (breaths/minute)
Returning to normal 34 (85) 33 (76.7) 0.341c
Not returning to normal 6 (15) 10 (23.3)
Pulse (x/minute)
Returning to normal 34 (85) 34 (79.1) 0.483c
Not returning to normal 6 (15) 9 (20.9)
Temperature (°C)
Returning to normal 25 (62.5) 30 (69.8) 0.484c
Not returning to normal 15 (37.5) 13 (30.2)
aAnalysis by t-test, banalysis by Mann–Whitney, canalysis by Chi-square
Table 3: Parameters of the direct medical cost of participants 




Preparation A (n=40) Preparation B (n=43)
Direct medical 
cost
458,290±23,828 IDR 408,347±19,728 IDR
Laboratory 
examination cost
125,000 IDR 125,000 IDR
Doctor visit cost 98,375±17,773 IDR 87,558±14,284 IDR
Disposable 
material cost
30,000 IDR 30,000 IDR
Room cost 107,375±11,435 IDR 101,744±10,112 IDR
Parenteral 
nutrition cost
97,540±3,109 IDR 64,044±1893 IDR
SD: Standard deviation
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nutrition cost was adjusted as per an annual inflation rate of 6%. Other 
costs were not adjusted for inflation (Table 3).
Table 4 proves that parenteral nutrition involves a higher cost than 
conventional nutrition. Parenteral nutrition components are more 
complex than conventional nutrition components; therefore, they incur 
a higher cost for both, provision and distribution.
Sensitivity analysis showed that there was no difference with the base 
case. Preparation A (D10-CaGluconate) was part of the first quadrant, 
which had higher cost and higher effectivity. Meanwhile, preparation B 
(D5 1/4NS) was part of the third quadrant, which had lower cost with 
lower effectivity (Fig. 1). Sensitivity analysis with respect to effectivity 
change of preparation A and preparation B are shown in Table 5. 
Preparation A was the first choice because its effectivity level was 
greater than that of preparation B. However, preparation B could be 
a treatment alternative for RDS. Preparation A was more cost effective 
than preparation B, with or without the 50% simulation of the increase 
and decrease in the effectivity costs of up to 3,359,194 IDR (decrease of 
50%) and 10,077,582 IDR (increase of 50%) (Table 6). Table 7 shows the 
sensitivity analysis cost compared to the change in the direct medical cost, 
with or without the 1.5% simulation. Preparation A was also more cost-
effective in terms of the daily direct medical costs, with or without the 
1.5% simulation of decrease of 9,866,951 IDR and increase of 10,167,468 
IDR (Table 8). Total average cost-effectiveness ratio (ACER) score of the 
direct medical cost in each patient with preparation A from all effectivity 
was 6,791,720 IDR/effectivity. Meanwhile, in preparation B, the total 
cost was 23,789,458 IDR/effectivity. Therefore, the mean incremental 
cost-effectiveness ratio (ICER) direct medical cost of preparation B, 
compared to that of preparation A was 10,017,210 IDR. The ACER 
score of parenteral nutrition in each patient of Groups A and B from all 
effectivity was 1,498,674 IDR/effectivity and 1,065,194 IDR/effectivity, 
respectively. Therefore, the mean ICER parenteral nutrition cost of 
preparation B compared to that of preparation A was 6,718,388 IDR. 
Table 9 shows the threshold analysis to the change of ICER score with the 
score of 3 × gross domestic product (GDP) is US$10,425.9.
DISCUSSION
Neonatal patients diagnosed with RDS tend to have a low blood sugar 
level or hypoglycemia. Thus, blood glucose levels must be closely 
monitored. Hypoglycemia occurs if the blood glucose level falls below 
40 mg % (serum or plasma glucose >10-15%). This is probably caused 
by a defect in the glucose production, glucose overconsumption, or 
both. Low birth weight neonates; premature neonates; neonates with 
asphyxia or macrosomia; and neonates with signs of hypoglycemia must 
be examined in cases of hypoglycemia, especially if the oral nutrition 
consumption of the mother during pregnancy was poor. The normal 
blood glucose level of neonates is 50-80 mg/dL. Delayed treatment 
may cause permanent brain damage, especially in low-weight and 
premature neonates. Chronic or recurring hypoglycemia can also affect 
Table 4: Parameters of the direct medical cost of participants 





Parenteral nutrition cost 3,901,600 IDR 2,753,900 IDR
Lowest 92,850 IDR 62,300 IDR
Highest 99,550 IDR 66,050 IDR
Laboratory examination cost 5,000,000 IDR 5,375,000 IDR
Disposable material cost 1,200,000 IDR 1,290,000 IDR
Doctor visit cost 3,935,000 IDR 3,765,000 IDR
Lowest 70,000 IDR 70,000 IDR
Highest 150,000 IDR 150,000 IDR
Perinatology room cost 4,295,000 IDR 4,375,000 IDR
Lowest 100,000 IDR 70,000 IDR
Highest 125,000 IDR 125,000 IDR
Total cost of all samples 18,331,600 IDR 17,558,900 IDR
Mean total cost for each patient 458,290 IDR 408,347 IDR
Table 5: Sensitivity analysis with respect to effectivity change
Effectivity −50% +50%
Weight (g)
Preparation A 14.240 IDR 42.720 IDR
Preparation B 11.745 IDR 35.235 IDR
Blood glucose level (mg/dL)
Preparation A 13.365 IDR 40.095 IDR
Preparation B 13.21 IDR 39.630 IDR
Respiratory rate (breaths/minute)
Preparation A −6.175 IDR −18.525 IDR
Preparation B −3.885 IDR −11.655 IDR
Pulse frequency (×/minute)
Preparation A −5.490 IDR −16.470 IDR
Preparation B −4.035 IDR −12.105 IDR
Temperature (°C)
Preparation A 0.0065 IDR 0.0195 IDR
Preparation B 0.0060 IDR 0.0180 IDR




Preparation B A 3.356 IDR 10.069 IDR
Blood glucose level (mg/dL)
Preparation B A 54.026 IDR 162.077 IDR
Respiratory rate (breaths/minute)
Preparation B A −3.657 IDR −10.970 IDR
Pulse frequency (×/minute)
Preparation B A −5.755 IDR −17.266 IDR
Temperature (°C)
Preparation B A 16,748,000 IDR 50,244,000 IDR
ICER preparation B A 16,795,970 IDR 50,387,910 IDR
Mean ICER 3,359,194 IDR 10,077,582 IDR
ICER: Incremental cost-effectiveness ratio
Table 8: Sensitivity analysis of the direct medical cost compared 
to the change in the ICER score of the direct medical cost
ICER −1.5% +1.5%
Preparation B  A 9,866,951 IDR 10,167,468 IDR
ICER: Incremental cost-effectiveness ratio





Preparation A 451,416 IDR 465,164 IDR
Preparation B 402,222 IDR 414,472 IDR
Table 9: Threshold analysis to the change of the ICER score
ICER (effectivity) Treatment 
groups
Direct medical cost
Preparation B A 
Weight 10,009 IDR <US$10,425.9/year
Blood glucose level 161,107 IDR <US$10,425.9/year
Respiratory rate 10,905 IDR <US$10,425.9/year
Pulse frequency 17,163 IDR <US$10,425.9/year
Temperature 49,943,000 IDR <US$10.425.9/year
Threshold 3 × GDP US$10,425.9
ICER: Incremental cost-effectiveness ratio
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the development and function of the brain. When accompanied by 
ischemia and hypoxemia, hypoglycemia may cause permanent brain 
damage [6].
RDS has signs or symptoms as parameters for the diagnosis which 
must be treated. Respiratory distress is recognized as any signs of 
breathing difficulties in neonates [7]. Respiratory rate is one of the main 
parameters in the diagnosis of RDS. Patients who experience difficulty 
in breathing or cannot breathe must be treated immediately, otherwise 
it may lead to death. The second parameter is pulse frequency. RDS 
patients tend to experience tachycardia. When such a patient is not 
treated immediately, it could cause heart failure. The third parameter 
is body temperature. RDS patients have a high risk of hypothermia; 
thus, lighting with ultraviolet light or other warming methods must 
be done for treatment. All these conditions (apnea, tachycardia, and 
hypothermia) must be treated immediately to avoid permanent damage 
to the brain, paralysis, and death. Intensive care is crucial. The previous 
study showed that RDS occurs in 78% of neonates weighing 501-
1500 g, with 71% cases reported in neonates weighing 501-750 g, 54% 
in neonates weighing 751-1000 g, 36% in those weighing 1001-1250 g, 
and 26% in those weighing 1250-1500 g [8-11]. A study conducted 
by Gunn et al. suggested that infants with respiratory distress who 
weigh <1500 g may receive the greater benefit from total parenteral 
nutrition [12].
According to the previous studies [13], the values of the cost incurred 
in health programs must be adjusted each year, by 3.5% in England 
and 4% in France. Both countries need sensitivity analysis using 
alternative discounted medical cost (1.5% in England; 3% and 6% in 
France). In France, after 30 years, the discounted medical cost should 
be progressively decreased by 2%. The National Institute for Clinical 
Excellence (NICE) has set the lowest price or discounting for each 
therapy with long-term medical benefit at 1.5%. Therefore, simulation 
of the increase and decrease in the cost by 50% is used for effectivity. 
In this study, the author used the adjustment score suggested by NICE 
(1.5%). Indonesia, as a developing country, does not have its own 
established sensitivity score cost. Previous studies have recommended 
simulation scores of 5%, 15%, and 20% for the simulation of the 
increased and decreased costs.
As per our knowledge, no previous study has conducted a cost-
effectiveness analysis between parenteral D10-CaGluconate and 
conventional D5 1/4NS nutrition preparations. If there were two or 
more medical interventions with the same purpose but different levels 
of effectiveness, cost-effectiveness would be the deciding factor for 
selecting the method. Based on threshold analysis, we can conclude 
that the cost incurred for RDS patients was relatively under the GDP. 
In other words, it was still suitable with medication rationality. This 
retrospective cohort research used 83 samples, including 40 D10-
CaGluconate samples and 43 D5 1/4NS samples. The following 
secondary data used in this research were obtained from the patients’ 
medical records: Neonates weight, blood glucose level, respiratory rate, 
pulse frequency, body temperature, and medical cost. It was found that 
the patients’ diseases were not homogenous and had severe variations; 
in addition, there were some non-specific diagnoses. The significance 
of the statistical test was low due to its weak power. Advanced studies 
need to be conducted to evaluate the effect of bias factors on the 
effectiveness of the preparation.
CONCLUSION
The D10-CaGluconate preparation was more cost-effective than the 
D5 1/4NS preparation. However, the D5 1/4NS preparation could serve 
as an alternative treatment for RDS in normal-weight neonatal patients. 
To conclude, further studies on parenteral nutrition that involve more 
complex parenteral preparations need to be conducted to determine 
the actual effectiveness of a parenteral nutrition preparation.
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